Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct;6(4):227-34.
doi: 10.4103/0974-1208.126285.

Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation

Gottumukkala Achyuta Rama Raju  1 , Rahul Chavan  2 , Mamata Deenadayal  3 , Devika Gunasheela  4 , Rohit Gutgutia  5 , Geetha Haripriya  6 , Mirudhubashini Govindarajan  7 , Nayana Hitesh Patel  8 , Ameet Shashikant Patki  9
Affiliations
Review

Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation

Gottumukkala Achyuta Rama Raju et al. J Hum Reprod Sci. 2013 Oct.

Abstract

Luteinizing hormone (LH) in synergy with follicle stimulating hormone (FSH) stimulates normal follicular growth and ovulation. FSH is frequently used in assisted reproductive technology (ART). Recent studies have facilitated better understanding on the complementary role of the LH to FSH in regulation of the follicle; however, role of LH in stimulation of follicle, optimal dosage of LH in stimulation and its importance in advanced aged patients has been a topic of discussion among medical fraternity. Though the administration of exogenous LH with FSH is obligatory for controlled ovarian stimulation in patients with hypogonadotropic hypogonadism, there is still a paucity of information of its usage in other patient population. In this review we looked in to the multiple roles that LH plays complementary to FSH to better understand the LH requirement in patients undergoing ART.

Keywords: Assisted reproductive techniques; follicle stimulating hormone; luteinizing hormone; ovarian hyper-stimulation.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: This review article is the result of a series of advisory board meetings supported by Merck Specialties Private Limited.

Figures

Figure 1
Figure 1
Two-cell, two-gonadotropin theory
Figure 2
Figure 2
Follicle stimulating hormone threshold and recruitment window
Figure 3
Figure 3
Luteinizing hormone therapeutic window
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril. 2002;77:1170–7. - PubMed
    1. Humaidan P, Bungum L, Bungum M, Andersen CY. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod. 2002;17:2016–21. - PubMed
    1. Lahoud R, Al-Jefout M, Tyler J, Ryan J, Driscoll G. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates. Hum Reprod. 2006;21:2645–9. - PubMed
    1. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril. 2007;87:542–6. - PubMed
    1. Pezzuto A, Ferrari B, Coppola F, Nardelli GB. LH supplementation in down-regulated women undergoing assisted reproduction with baseline low serum LH levels. Gynecol Endocrinol. 2010;26:118–24. - PubMed

LinkOut - more resources